Glioblastoma

Research team describes novel tumor treatment

In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos in Scientific Reports has been published.

Nov 24, 2015
popularity90 comments 0

Genome misfolding unearthed as new path to cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate ...

Dec 23, 2015
popularity29 comments 1

First look at how astrocytes function in humans

Pretty much everything happening in the brain would fail without astrocytes. These star-shaped glial cells are known to have a critical role in synapse creation, nervous tissue repair, and the formation of the blood-brain ...

Dec 10, 2015
popularity95 comments 1

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Study suggests remarkable approach to MS treatment

(Medical Xpress)—Multiple sclerosis (MS) is an autoimmune inflammatory disorder in which the immune system attacks the myelin sheath enveloping and insulating the nerves. A progressive disease that often results in severe ...

Proteomics and precision medicine

As medical professionals search for new ways to personalize diagnosis and treatment of disease, a research team at the University of Iowa has already put into practice what may be the next big step in precision medicine: ...

The amazing axon adventure

How does the brain make connections, and how does it maintain them? Cambridge neuroscientists and mathematicians are using a variety of techniques to understand how the brain 'wires up', and what it might be able to tell ...